GERMANY - HBM BioVentures/ BioCapital leads series-C mtm investment

A consortium of investors has led a series-C financing of mtm laboratories. The round will enable the company to fund the clinical development and commercialisation of its proprietary diagnostic and screening devices in the field of cervical cancer. mtm is based in Heidelberg and has developed a number of bio-markers for cervical cancer. It also has operations in Westborough, near Boston.